Showing 1361-1370 of 1614 results for "".
- Horus Pharma Group Launches Nordic Subsidiaryhttps://modernod.com/news/horus-pharma-group-launches-nordic-subsidiary/2481515/Horus Pharma, an independent French laboratory specializing in ophthalmology, has opened of a new subsidiary. From its base in Stockholm, Sweden, Horus Pharma Nordic will cover Sweden, Norway, Finland and Denmark. Horus Pharma develops, patents and markets preservative-free ey
- Survey: Employees Value Vision Care as Much as Dental, but Many are Leaving Benefits on the Tablehttps://modernod.com/news/survey-employees-value-vision-care-as-much-as-dental-but-many-are-leaving-benefits-on-the-table/2481495/A new survey conducted by The Harris Poll for XP Health finds that employees value vision care as much as dental, but many are confused about how to take advantage of it—even when they have vision benefits. According to the
- CooperVision Launches Major US Myopia Control Advocacy and Education Campaignhttps://modernod.com/news/coopervision-launches-major-us-myopia-control-advocacy-and-education-campaign/2481474/CooperVision has unveiled a multifaceted consumer and professional marketing campaign to protect children’s vision and advance myopia control education in the United States to kick off Vision Expo East 2023. The “Make Children’s Sight Your Fight” initiative is rooted in ne
- Cedars-Sinai Analysis Evaluates How Retinal Changes Correspond to Cognitive Changes in Alzheimer’s Diseasehttps://modernod.com/news/new-insights-eye-damage-in-alzheimers-disease-patients/2481455/Cedars-Sinai investigators have produced an analysis evaluating how retinal changes correspond to brain and cognitive changes in Alzheimer’s disease patients. Investigators looked at retinal and brain tissue samples collected over 14 years from 86 human donors—the
- Oculis Announces US Public Listing on Nasdaqhttps://modernod.com/news/oculis-announces-us-public-listing-on-nasdaq/2481444/Starting today, Oculis’ shares will trade on the Nasdaq Stock Market under the ticker symbol "OCS." The listing comes after successfully closing the business combination between European Biotech Acquisition Corp. (EBAC) and Oculis SA. The business combination was un
- Study: Zebrafish Model Helps Explain Eye Developmenthttps://modernod.com/news/study-zebrafish-model-helps-explain-eye-development/2481352/Scientists at the National Eye Institute (NEI) have developed a zebrafish model of NEDBEH—a rare genetic disorder that can cause coloboma, where parts of the eye are missing due to developmental defects. The model provides a new tool for understanding the eye's embryonic developmen
- Rayner Launches ‘Peer2Peer: The Podcast’ for Clinical Educationhttps://modernod.com/news/rayner-launches-peer2peer-the-podcast-for-clinical-education/2481342/Rayner announced the launch of the latest addition to their Peer2Peer clinical education platform, "Peer2Peer: The Podcast." Topics included in the podcase include the do's and don’ts of implanting toric IOLs; marketing your clinic online; popular
- Neurotech Pharmaceuticals Appoints Scott Hunter as Chief Commercial Officerhttps://modernod.com/news/neurotech-pharmaceuticals-appoints-scott-hunter-as-chief-commercial-officer/2481341/Neurotech Pharmaceuticals announced the expansion of its executive team with the appointment of Scott Hunter as Chief Commercial Officer bringing two decades of eye care experience across both rare disease and specialty markets. “Scott’s appointment as the company&rsquo
- Verana Health Study of Patients with Dry AMD Published in International Ophthalmologyhttps://modernod.com/news/verana-health-study-of-patients-with-dry-amd-published-in-international-ophthalmology/2481301/Verana Health—a digital health company elevating quality in real-world data—announced that Ophthalmology and Therapy, an international, peer-reviewed medical journal, has
- Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosishttps://modernod.com/news/ocugen-announces-ocu400-receives-orphan-drug-designations-for-retinitis-pigmentosa-and-leber-congenital-amaurosis/2481300/Ocugen announced that the FDA granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3)—for the treatment of retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA). “Receiving orphan drug designation is